Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-29
2011-03-29
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S249000, C544S122000, C544S295000
Reexamination Certificate
active
07915256
ABSTRACT:
Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
REFERENCES:
patent: 6316444 (2001-11-01), Hunt et al.
patent: 2005/0009832 (2005-01-01), Sun
patent: 2007/0281943 (2007-12-01), Andrews et al.
patent: 2008/0090818 (2008-04-01), Andrews et al.
patent: 02056888 (2002-07-01), None
patent: 2004037814 (2004-05-01), None
patent: 2004072081 (2004-08-01), None
patent: 2005120513 (2005-12-01), None
patent: 2006053121 (2006-05-01), None
patent: 2006086545 (2006-08-01), None
Data Base PubChem Substances XP 002447690, K00159—Apr. 14, 2006.
Data Base PubChem Substances XP 002447691, BioFocus 190—027—7467—Oct. 20, 2006.
Aberg, E, et al, “Regulation of MAPK-activated Protein Kinase 5 Activity and Subcellular Localization by the Atypical MAPK ERK4/MAPK4,” The Journal of Biological Chemistry, vol. 281, No. 46, Nov. 17, 2006, pp. 35499-35510, US.
Bain, J, et al, The specificities of protein kinase inhibitors: an update, Biochem, J.,(2003), 371, pp. 199-204, GB.
Folmer, F, et al, “Inhibition of TN Fa-induced activation of nuclear factor KB by kava (Piper methysticum) derivatives,” Biochemical Pharmacology, 71, (2006) pp. 1206-1218, Scotland.
Gaestel, M, “MAPKAP kinases—MKs—two's company, three's a crowd,” Nature, 2006, pp. 120-130, Germany.
Kant, S, et al, “Characterization of the Atypical MAPK ERK4 and Its Activation of the MAPK-activated Protein Kinase MK5,” Journal of Biological Chem, vol. 281, No. 46, Nov. 17, 2006, pp. 35511-35519, US.
New, Liguo, et al, PRAK, a novel protein kinase regulated by the p38 MAP kinase, The EMBO Journal, vol. 17, No. 12, 1998, pp. 3372-3384, US.
New, Liguo, et al, “Regulation of PARK Subcellular Location by p38 MAP Kinases,” Molecular Bio of the Cell, 243, pp. 2603-2616, US, Jun. 2003.
Ni, Hong, et al, “MAPKAPK5, a Novel Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase, Is a Substrate of the Extracellular-Regulated Kinase (ERK) and p38 Kinase,” Biochem & Biophys Research Comm, 243, (1998) pp. 492-496, US.
Schumacher, S, et al, “Scaffolding by ERK3 regulates MK5 in development,” The EMBO Journal, vol. 23, No. 24 (2004) pp. 4770-4779, Germany.
Seternes, O, et al, “Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway,” The EMBO Journal, vol. 23, No. 24 (2004) pp. 4780-4791, UK.
Seternes, O, et al, “Both Binding and Activationof p38 Mitogen-Activated Protein Kinase (MAPK) Play Esstential Roles in Regulation of the Nucleocytoplasmic Distribution of MAPK-Activated Protein Kinase 5 by Cellular Stress,” Molecular and Cellular Biology, vol. 22, No. 20, Oct. 2002, pp. 6931-6945, US.
Shi, Y, et al, “Elimination of Protein Kinase MK5/PRAK Activity by Targeted Homologous Recombination,” Molecular and Cellular Biology, vol. 23, No. 21, Nov. 2003, pp. 7732-7741, US.
Sun, P, et al, “PRAK Is Essential for ras-Induced Senescence and Tumor Suppression,” Cell 128, Jan. 26, 2007, pp. 295-308, US.
Dowling, J. et al., “Synthesis of [1 ,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists,” Bioorganic & Medicinal Chemistry Letters (15), (21) p. 48090-4813 (2005) US.
Peng, H. et al, “First Synthesis of Piperazine-derived [1,2,4]trazolo[1,5-a]pyrazine as an adenosine A2A receptor antagonist,” Heterocycles, col. 64, No. 19, (2005) pp. 2321-2327, US.
Andrews Martin James Inglis
Bar Gregory
Chambers Mark Stuart
Clase Juha Andrew
Edwards Paul
Galapagos NV
Klauber & Jackson LLC
Rao Deepak
LandOfFree
Triazolopyrazine compounds useful for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolopyrazine compounds useful for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolopyrazine compounds useful for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635237